According to the business intelligence report ‘Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market 2021-2028’, available with Market Study Report, global non-alcoholic steatohepatitis biomarker market is slated to grow at an annual rate of 21.28% CAGR between 2021-2028.
 

Rising occurrence of metabolic comorbidities, coupled with increasing incidence of non-alcoholic steatohepatitis are the key factors spurring global non-alcoholic steatohepatitis biomarker market outlook.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3584756/
 

While growing awareness regarding non-alcoholic fatty liver diseases (NAFLD) will boost the demand for biomarkers, unavailability of specialized diagnostic tests for the same, along with side effects of NASH therapeutics will act as challenges for businesses in this domain.   
 

The report studies the market at both micro and macro levels by fragmenting it into segments based on type, and industry verticals. Crucial metrics such market share captured, growth rate projections, and estimated valuation of each segment are also included.
 

Based on type, global non-alcoholic steatohepatitis biomarker market is divided into serum biomarker, apoptosis biomarker, hepatic fibrosis biomarker, oxidative stress biomarker, and others. Moving on to industry verticals, the business sphere is split into hospital, diagnostic lab, academic research key, and pharmaceutical & CRO industry.
 

From regional frame of reference, Asia Pacific market is projected to showcase lucrative growth trends between 2021-2028 due to developments in healthcare infrastructure, increasing occurrence of NASH, and better economic conditions. Growing healthcare awareness in developing countries like China and India will contribute to the market share as well.
 

Key players profiled in worldwide non-alcoholic steatohepatitis biomarker market report are Cadila Healthcare Limited, Allergan Inc., Viking Therapeutics Inc., AstraZeneca plc, Siemens Healthineers AG, Bristol Myers Squibb Company, Pfizer Inc., Genfit S.A., Novo Nordisk A/S, Gilead Sciences Inc., Novartis International AG, Madrigal Pharmaceuticals Inc., and Merck & Co. Inc.
 

These companies have undertaken strategic decisions such as mergers & acquisitions, product launches, collaborations, partnerships, and investments in R&D activities to enlarge their profit margins and strengthen their foothold in this business domain.